Objectives: Emerging evidence shows that methicillin-resistant Staphylococcus aureus (MRSA) infections caused by isolates with higher vancomycin MICs within the susceptibility range are associated with adverse outcomes. No study, however, has examined different susceptibility tests in predicting treatment outcomes of MRSA infections.
Introduction
Vancomycin is the most commonly used antimicrobial agent in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in many countries because of its predictable activity against MRSA. 1 The clinical use of vancomycin is, however, threatened by increasing reports of a higher likelihood of mortality or treatment failure among patients infected with MRSA presenting with a vancomycin MIC at the high end of the susceptible range. 2 -5 On the basis of pharmacodynamic plausibility and available clinical evidence, alternative anti-MRSA agents have been suggested if a vancomycin MIC of ≥2 mg/L is identified for the causative MRSA isolate, especially for patients with persistent disease or critical illness. 6 -8 In applying this recommendation in daily practice it is important to use a susceptibility testing method that can reliably detect in vitro vancomycin resistance and efficiently predict in vivo treatment outcomes. However, the conclusions of previous MRSA outcome studies supporting the effect of high vancomycin MIC on mortality have been determined predominantly from Etest results. 8 Because previous studies have shown significant differences in vancomycin MICs obtained from different susceptibility testing methods, 9 -14 it is difficult to generalize the results observed with the Etest to other testing methods in the treatment of patients infected with an MRSA strain that shows laboratory evidence of reduced vancomycin susceptibility.
In this study, we hypothesized that different susceptibility testing methods possess different MIC detection and outcome prediction capabilities owing to their intrinsic method-specific design, and are therefore able to be compared in parallel at the same cut-off value. Five susceptibility testing methods -agar dilution, the Etest and three commonly used automated systems -were simultaneously evaluated in this study. We aimed to understand the agreement between tests and, more importantly, to evaluate the outcome prediction capabilities of different susceptibility testing methods for better guidance on MRSA treatment.
Patients and methods

Study design, setting and patient selection
This retrospective cohort study was conducted in the Emergency Department (ED) of National Taiwan University Hospital. This 2500 bed university-affiliated teaching hospital provides both primary and tertiary care in northern Taiwan and has an average of 67000 patient discharges and 100000 patient ED visits annually. All ED patients aged ≥15 years diagnosed with MRSA bacteraemia from 1 January 2001 to 31 December 2011 were initially included. For patients with repeated MRSA bacteraemia during the study period, only the first episode was considered. Patients with MRSA bacteraemia were then excluded if the bloodstream isolate was not available for antimicrobial susceptibility testing or the patient was subsequently hospitalized and treated outside the study hospital. These patients with MRSA bacteraemia constituted the main study groups, and their bloodstream isolates were used for the comparison of vancomycin MIC results between different testing methods. To evaluate the performance of specific MIC susceptibility tests in predicting clinical outcomes, only patients with MRSA bacteraemia who received vancomycin as empirical therapy (patients with early mortality ≤3 days after obtaining the index blood culture) or definite antimicrobial therapy (patients who survived .3 days after obtaining the index blood culture) were included in the outcome predictability analysis. This study was approved by the institutional review board of the hospital, and the requirement for informed consent from each patient was waived.
Data collection, and information on variables and outcomes
Patient data included demographics, healthcare-associated exposure history within the past year, pre-existing comorbidities, initial presentations and empirical antimicrobial therapy in the ED. The subsequent hospitalization course, definitive antimicrobial therapy, primary site of infection, vancomycin trough level (if available) and all-cause mortality were determined from the medical records.
A full description of the definition of healthcare-associated exposure has previously been reported. 15 The severity of pre-existing comorbidities was assessed using the modified Charlson comorbidity score. 16 Initial vital signs on ED presentation were classified according to the International Sepsis Definitions. The severity of acute illness as assessed by the sepsis syndrome criteria was graded as: no sepsis or simple sepsis; severe sepsis; and septic shock. 17, 18 Inadequate vancomycin therapy was defined as a vancomycin trough level of ,10 mg/L measured ≥3 days but ,1 week after starting vancomycin therapy. All-cause in-hospital mortality was used as the main outcome variable in this retrospective study.
Microbiological procedures and determination of vancomycin MICs
Blood culture specimens were inoculated into BACTEC standard culture bottles or BACTEC PLUS culture bottles in a BACTEC 9000 system (Becton Dickinson, Sparks, MD, USA 21 All laboratory procedures were performed by experienced microbiology laboratory technicians who were blinded to the clinical outcome of the study patients. S. aureus ATCC 29213 was used as a control strain for all methods.
Statistical analysis
Binary variables were compared using the x 2 test. Age and the Charlson comorbidity score were compared using the independent Student t-test. Vancomycin values of all testing methods were categorized into low-and high-MIC groups at cut-off values of ,2 mg/L and ≥2 mg/L, respectively. We used three approaches -essential agreement, categorical agreement and very major error -to examine the inter-test agreements between the different testing methods. Essential agreement between the agar dilution method and the other four methods (Etest, MicroScan, VITEK-2 and Phoenix) was defined as a difference between MICs of +1 log 2 dilution or less using the agar dilution method as the reference standard. 22 Categorical agreements between the five testing methods were evaluated as the percentage of isolates that had concordant test results in determining high (≥2 mg/L) and low (,2 mg/L) vancomycin MIC values. A very major error for the Etest, MicroScan, VITEK-2 or Phoenix was defined as a high-MIC isolate (≥2 mg/L) determined using the agar dilution method that was interpreted as a low-MIC isolate (,2 mg/L) by the indicated testing method.
Sensitivity, specificity, positive predictive value and negative predictive value with associated 95% CIs of different MIC testing methods in capturing cases of mortality were obtained using standard definitions and methods. 23 We performed forward, backward and manual stepwise multivariate logistic regression modelling to understand the independent role of method-specific high vancomycin MIC values in predicting in-hospital mortality of vancomycin-treated patients with MRSA bacteraemia. Age was included throughout the model construction process because of its potential effect on mortality. The ability to predict mortality for different susceptibility tests was evaluated separately by including the 'high vancomycin MIC isolate' variable determined using a specific testing method with other potential confounding factors identified on univariate analysis (P≤ 0.10) into the multivariate regression modelling. Finally, the discriminatory ability of different MIC testing methods was assessed by the area under Chen et al.
the receiver operating characteristic curve of the final model integrating the method-specific 'high vancomycin MIC isolate' variable. 24 Data were analysed with SPSS for Windows version 16.0 (SPSS, Chicago, IL, USA) and CART software (Salford Systems). All P values are two-sided, and P,0.05 was considered statistically significant.
Results
Patients
We initially considered 432 non-duplicate episodes of MRSA bacteraemia recorded during the 11 year study period. Nine patients were excluded because they received treatment outside the study hospital, and 30 patients were excluded because their bloodstream isolates were not available for antimicrobial susceptibility testing. In total, 393 patients with MRSA bacteraemia were finally enrolled in this study for the evaluation of measurement agreement between different MIC testing methods. To evaluate the performance of a specific MIC testing method in predicting treatment outcome, only clinical data from 310 patients with MRSA bacteraemia who received vancomycin therapy were used in the outcome predictability analysis. The clinical characteristics of all study patients (n¼ 393) and of the 310 vancomycin-treated patients are detailed in Table 1 . Table 6 ). The AUCs of agar dilution-and Etest-incorporated regression models in predicting mortality were 0.743 (95% CI, 0.683-0.803) and 0.751 (95% CI, 0.692 -0.810), respectively ( Figure 1) . Finally, if the clinical data from 81 patients who did not have measured vancomycin trough levels and 48 patients who received inadequate vancomycin therapy were further excluded, a high vancomycin MIC isolate identified by either the agar dilution or the Etest method remained an independent predictor of mortality (aOR, 2.722; 95% CI, 1.071-6.918; and aOR, 3.306; 95% CI, 1.060-10.306, respectively) in multivariate logistic regression models controlling for other confounders including age, malignancy, thrombocytopenia, endovascular infection and lower respiratory tract infection.
Method-specific vancomycin MIC values and measurement agreement
Discussion
We specifically evaluated the performance of different vancomycin susceptibility testing methods in predicting the in-hospital mortality of vancomycin-treated patients with MRSA bacteraemia. There are three notable findings in this study. First, although remarkably good essential agreements were observed, categorical agreements differed significantly across different susceptibility testing methods for vancomycin MICs for MRSA isolates. Second, vancomycin MICs determined using the three automated susceptibility testing systems failed to predict the mortality of patients with MRSA bacteraemia. Third, both agar dilution and the Etest effectively stratified the risk of in-hospital mortality of patients with MRSA bacteraemia independently of the effect from other confounding factors. Furthermore, at the same cut-off value (≥2 mg/L), the Etest method had a higher predictability for treatment outcome of MRSA infections compared with the agar dilution method.
Many previous studies have evaluated the accuracy of different susceptibility tests in determining vancomycin MICs using different reference standards. 9 -14 Although poor measurement agreement between susceptibility tests has been observed, as shown again by this study, no study has comprehensively evaluated the clinical performance of different tests in predicting the clinical outcome Categorical agreement between the five study susceptibility testing methods was measured as the percentage of isolates that had concordant test results when determining high (≥2 mg/L) and low (,2 mg/L) vancomycin MICs. Predicting mortality by different MIC tests of patients with MRSA infection. A study by Hsu et al.
11 found better outcome predictability for patients with MRSA infection with the Etest method than the VITEK Legacy automated system. However, the study was limited by the small sample size, the use of end-of-treatment response rather than mortality as the outcome variable and failure to control the severity of chronic comorbidity. Our study therefore provides strong clinical evidence supporting the previous observation that strains of staphylococci with reduced vancomycin susceptibility are best detected by nonautomated quantitative testing methods. 16 The failure of MIC determination by the three automated methods to predict mortality in the current study is an important finding and deserves further discussion. Both the MicroScan and Phoenix automated systems use the broth microdilution method and determine the MIC by turbidity. However, the MicroScan system interprets the MIC values after a full 24 h of incubation and the Phoenix system interprets them at 6-16 h (12 h on average). The difference in MIC reading times might influence the turbidity of the incubating broth and therefore the MIC results. Different from the MicroScan and Phoenix systems, the VITEK-2 system continuously monitors bacterial growth on susceptibility cards containing different vancomycin concentrations during an abbreviated incubation period. The VITEK-2 system infers the vancomycin MIC result by comparing the growth curve of the index isolate with the curves of reference isolates in a computerized database, which is different from the standard method recommended by the CLSI. The method-specific design of different automated susceptibility testing systems might therefore contribute to their performance in predicting outcome in patients with MRSA bacteraemia. In the current study, although both the agar dilution and Etest methods were useful in predicting mortality, we found that the Etest had better ability to predict mortality than the agar dilution method, as selected by final multivariate logistic regression modelling. Because vancomycin MIC results generated by the Etest tend to be 0.5-1 log 2 dilution higher than those generated by the CLSI broth or agar dilution methods, 12 it was postulated that an effect of high vancomycin MIC at 2 mg/L on patient mortality would be more easily observed in studies using the Etest as the susceptibility testing method given in studies with a limited number of cases. This might explain why previous outcome studies supporting an effect of high vancomycin MIC have predominantly been based on the results of the Etest rather than the broth or agar dilution methods.
Although we postulated that a high vancomycin MIC affects patient outcomes by reducing the probability of achieving an optimal ratio of AUC at 24 h (AUC 24h ) to MIC target, 25, 26 other explanations do exist. First, isolates with a high vancomycin MIC may contain a high percentage of heteroresistant vancomycinintermediate S. aureus and contribute significantly to patient mortality. 27, 28 Second, MIC may be a surrogate marker for strainspecific virulence that affects patient mortality. 18, 29 It is especially important to understand the interactive effect of vancomycin MIC and strain type on patient outcome because more and more MRSA infections occurring in hospitals are due to novel communityassociated MRSA strains. 30 There are limitations in this study. First, this was a single-centre study conducted in Taiwan. The generalizability of the study findings to other communities, where the circulating MRSA strains might differ, requires further confirmation. Second, the clinical data from this observational cohort were retrospectively collected and therefore subject to information bias. However, we tried to minimize such bias by using in-hospital mortality as the primary study outcome, for which information could be accurately obtained for all study patients. Third, the vancomycin MIC values in this study were determined using MRSA isolates stored for .6 months from the time of isolation. Recent evidence has shown that frozen storage significantly affects the MICs for MRSA isolates, and has an inconsistent effect if different antimicrobial agents are tested or susceptibility test methods adopted. 31 Our study findings therefore need to be validated in a prospective manner using MIC values measured at the time of isolation. Finally, though agar dilution is an accepted CLSI reference method, the broth microdilution method is more commonly used as the reference standard in contemporary studies. Though discrepancy between the two reference methods in MIC determination has been observed, many studies have also shown that agar dilution has very good agreement with broth microdilution for many antibiotics, including vancomycin. One study even found that the essential agreement between the two reference methods for vancomycin MIC was 96.4+2.5% and categorical agreement was 100%. 32 In conclusion, a subtle increase in vancomycin MICvalues within the current susceptibility window is associated with a higher risk of mortality among patients with MRSA bloodstream infections. The effect on patient mortality is independently predicted by both the agar dilution and Etest methods. This is especially important for patients with MRSA infection with vancomycin MICs ≥2 mg/L identified either by agar dilution or the Etest. Clinicians should consider these MRSA strains to be vancomycin non-susceptible for patients with MRSA bloodstream or invasive infections. None of the automated susceptibility testing systems showed predictability for mortality in vancomycin-treated patients with MRSA bacteraemia. Because the categorical measurement agreement between different susceptibility testing methods in identifying a high vancomycin MIC MRSA isolate is generally low, the results from automated systems cannot simply be inferred from those of non-automated quantitative testing methods when deciding on antimicrobial therapy. 
